Homotypic Cell Membrane-Cloaked Biomimetic Nanocarrier for the Targeted Chemotherapy of Hepatocellular Carcinoma

Overview

Journal Theranostics

Date 2019 Sep 20

PMID 31534522

Citations 23

Authors

Xiaojun Liu

Yingxue Sun

Shushen Xu

Xiaonan Gao

Fanpeng Kong

Kehua Xu

Bo Tang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) has been reported to be the third most common malignant tumor and has the highest rate of mortality. To increase the chemotherapy efficacy of HCC, a drug delivery system featured with desirable active targeting ability, delivery efficiency and immune evasion is in high demand. We have developed a drug nanocarrier by utilizing a homotypic cancer cell membrane for targeted chemotherapy of HCC. Structurally, the homotypic HepG2 cell membrane was used as the cloak, and a poly (lactic--glycolic acid) (PLGA) nanoparticle as the core, resulting in the nanocarrier . The nanoparticles exhibit excellent targeting ability toward HepG2 cells. Doxorubicin (Dox) carried by possesses high delivery efficiency and a remarkable therapeutic effect. In experiments, delivers Dox directly to the tumor lesion of nude mice, and tumor volume decreases by approximately 90% after treatment. We have developed a drug nanocarrier by utilizing a homotypic cancer cell membrane for targeted chemotherapy of HCC with excellent active targeting ability. This biomimetic platform not only effectively treats HCC but also provides a sound strategy for the treatment of other cancers changes in the corresponding homotypic cancer cell membrane.

Citing Articles

Seeing beyond words: nanotechnology in hepatocellular carcinoma - a bibliometric study.

Tuergan T, Abulaiti A, Tulahong A, Zhang R, Yuan Z, Lin Y Front Oncol. 2025; 14:1487198.

PMID: 39882441 PMC: 11774701. DOI: 10.3389/fonc.2024.1487198.

" philosophy" for the design of anticancer drug delivery nanoparticles.

Ai Y, Tian Y, Qiao J, Wang C, Li H Biomater Transl. 2024; 5(2):144-156.

PMID: 39351167 PMC: 11438609. DOI: 10.12336/biomatertransl.2024.02.005.

Targeted Drug Delivery Strategies for the Treatment of Hepatocellular Carcinoma.

Liu Y, Wu Y, Li Z, Wan D, Pan J Molecules. 2024; 29(18).

PMID: 39339402 PMC: 11434448. DOI: 10.3390/molecules29184405.

Advances in cell membrane-based biomimetic nanodelivery systems for natural products.

Zhang Y, Zhang Q, Li C, Zhou Z, Lei H, Liu M Drug Deliv. 2024; 31(1):2361169.

PMID: 38828914 PMC: 11149581. DOI: 10.1080/10717544.2024.2361169.

Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform.

Guo Q, Wang S, Xu R, Tang Y, Xia X RSC Adv. 2024; 14(15):10608-10637.

PMID: 38567339 PMC: 10985588. DOI: 10.1039/d4ra01026d.

References

Seiffert M, Cant C, Chen Z, Rappold I, Brugger W, Kanz L . Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood. 1999; 94(11):3633-43. View

Pardoll D . Does the immune system see tumors as foreign or self?. Annu Rev Immunol. 2003; 21:807-39. DOI: 10.1146/annurev.immunol.21.120601.141135. View

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View

Glinsky V, Glinsky G, Glinskii O, Huxley V, Turk J, Mossine V . Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003; 63(13):3805-11. View

Frazer I . Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004; 4(1):46-54. DOI: 10.1038/nri1260. View

Sultan A, Xie J, LeBaron M, Ealley E, Nevalainen M, Rui H . Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene. 2004; 24(5):746-60. DOI: 10.1038/sj.onc.1208203. View

Torchilin V . Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2):145-60. DOI: 10.1038/nrd1632. View

Pack D, Hoffman A, Pun S, Stayton P . Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005; 4(7):581-93. DOI: 10.1038/nrd1775. View

Rabinovich G, Gabrilovich D, Sotomayor E . Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2006; 25:267-96. PMC: 2895922. DOI: 10.1146/annurev.immunol.25.022106.141609. View

10.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

11.

Iurisci I, Cumashi A, Sherman A, Tsvetkov Y, Tinari N, Piccolo E . Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res. 2009; 29(1):403-10. View

12.

Majeti R, Chao M, Alizadeh A, Pang W, Jaiswal S, Gibbs Jr K . CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138(2):286-99. PMC: 2726837. DOI: 10.1016/j.cell.2009.05.045. View

13.

Yan M, Du J, Gu Z, Liang M, Hu Y, Zhang W . A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat Nanotechnol. 2009; 5(1):48-53. DOI: 10.1038/nnano.2009.341. View

14.

Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W . Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release. 2010; 145(1):17-25. DOI: 10.1016/j.jconrel.2010.03.007. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Wang A, Langer R, Farokhzad O . Nanoparticle delivery of cancer drugs. Annu Rev Med. 2011; 63:185-98. DOI: 10.1146/annurev-med-040210-162544. View

17.

Du J, Du X, Mao C, Wang J . Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc. 2011; 133(44):17560-3. DOI: 10.1021/ja207150n. View

18.

Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M . Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011; 6(12):815-23. DOI: 10.1038/nnano.2011.166. View

19.

Schroeder A, Heller D, Winslow M, Dahlman J, Pratt G, Langer R . Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2011; 12(1):39-50. DOI: 10.1038/nrc3180. View

20.

Wang C, Jiang Y, Ma J, Wu H, Wacker D, Katritch V . Structural basis for molecular recognition at serotonin receptors. Science. 2013; 340(6132):610-4. PMC: 3644373. DOI: 10.1126/science.1232807. View